Scholarlink

Background <p>The impact of TTF-1 expression on outcomes in patients with non-squamous non-small cell lung cancer (NSCLC) has increasingly been reported. However, information on the characteristics and outcomes of patients with non-squamous NSCLC in whom TTF-1-negativity was confirmed using different antibody clones remains scarce.</p> Methods <p>We conducted a multicenter retrospective study and analyzed the data of patients with non-squamous NSCLC in which TTF-1-negativity was confirmed in each participating institution. Patients were eligible if they had an EGFR/ALK-wild type tumor and received first-line treatment with an immune checkpoint-containing regimen. Clinical information, including the TTF-1-antibody used in each institution, was collected.</p> Results <p>Data of 70 patients with non-squamous NSCLC and negative TTF-1 expression were analyzed. The patients were subdivided into SPT24- and 8G7G3/1-confirmed groups according to the TTF-1-antibody clone used to confirm TTF-1-negativity. Multivariate analysis using the Cox proportional hazard model revealed that the SPT24-confirmed group had a significantly increased risk of death (hazard ratio: 3.20, 95% confidence interval: 1.23 − 8.29), but not a significant association with the risk of disease progression. Meanwhile, the neutrophil/lymphocyte ratio was significantly associated with both the risk of disease progression and death.</p> Conclusion <p>TTF-1-negative non-squamous NSCLC patients who were diagnosed using the SPT24 antibody clone exhibited significantly shorter overall survival than those who were diagnosed using the 8G7G3/1 antibody clone, and NLR may be a useful predictor for the prognosis of patients with TTF-1-negative non-squamous cell NSCLC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Survival outcomes in TTF-1 negative non-squamous non-small cell lung cancer (H-LINK 001)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月22日

查看全文
  • Minehiko Inomata,
  • Yutaro Moriyasu,
  • Takeshi Tsuda,
  • Yukihiro Umeda,
  • Taro Yoneda,
  • Yutaka Takahara,
  • Koki Nakashima,
  • Tomomi Ichikawa,
  • Yuichi Tambo,
  • Hirokazu Taniguchi,
  • Shin Ishizawa,
  • Kenichi Hirabayashi,
  • Seiji Yano

摘要

Background

The impact of TTF-1 expression on outcomes in patients with non-squamous non-small cell lung cancer (NSCLC) has increasingly been reported. However, information on the characteristics and outcomes of patients with non-squamous NSCLC in whom TTF-1-negativity was confirmed using different antibody clones remains scarce.

Methods

We conducted a multicenter retrospective study and analyzed the data of patients with non-squamous NSCLC in which TTF-1-negativity was confirmed in each participating institution. Patients were eligible if they had an EGFR/ALK-wild type tumor and received first-line treatment with an immune checkpoint-containing regimen. Clinical information, including the TTF-1-antibody used in each institution, was collected.

Results

Data of 70 patients with non-squamous NSCLC and negative TTF-1 expression were analyzed. The patients were subdivided into SPT24- and 8G7G3/1-confirmed groups according to the TTF-1-antibody clone used to confirm TTF-1-negativity. Multivariate analysis using the Cox proportional hazard model revealed that the SPT24-confirmed group had a significantly increased risk of death (hazard ratio: 3.20, 95% confidence interval: 1.23 − 8.29), but not a significant association with the risk of disease progression. Meanwhile, the neutrophil/lymphocyte ratio was significantly associated with both the risk of disease progression and death.

Conclusion

TTF-1-negative non-squamous NSCLC patients who were diagnosed using the SPT24 antibody clone exhibited significantly shorter overall survival than those who were diagnosed using the 8G7G3/1 antibody clone, and NLR may be a useful predictor for the prognosis of patients with TTF-1-negative non-squamous cell NSCLC.